QURE News
Archived Headlines
- uniQure prices IPO at $17, above the range 02/05/14
- 12 US IPOs planned for the week of Feb 3 02/03/14
- US IPO Recap: Care.com tends to a slow-starting IPO market 01/27/14
- Gene therapy biopharma uniQure sets terms for $64 million IPO 01/24/14
- US IPO Recap: IMS Health files for potential billion-dollar offering 01/06/14
See more
Looking to fight Leukemia: Syros Pharmaceuticals files for a $69 million IPO
Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The Cambridge, MA-based company was founded in 2011. It plans to list on...read more
Gene therapy biotech Xenon Pharmaceuticals sets terms for $44 million IPO
Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, announced terms for its IPO on Monday. The Burnaby, Canada-based company plans to raise $44 million by offering 4.0 million shares at a price range of $10 to...read more
Rare disease biotech Xenon Pharmaceuticals files for a $52 million IPO
Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. Xenon has a number of collaboration and licensing agreements with...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more